Innate Pharma (NASDAQ:IPHA) Stock Rating Upgraded by Leerink Partners

Key Points

• Leerink Partners upgraded Innate Pharma to “outperform” from “market perform” and set a $4.00 price target, implying approximately 80% upside from the reported $2.22 share price.
• Analyst sentiment is broadly positive: Innate Pharma has a consensus “Moderate Buy” rating and an average price target of $6.33, supported by upgrades from Citigroup and a higher $7.00 target from HC Wainwright.
• IPHA shares have risen above their moving averages, opening at $2.22 versus 50-day and 200-day averages of $1.80 and $1.67, while institutional ownership remains very limited at 0.16%.

Innate Pharma (NASDAQ:IPHA - Get Free Report) was upgraded by analysts at Leerink Partners from a "market perform" rating to an "outperform" rating in a report issued on Tuesday, Marketbeat Ratings reports. The brokerage presently has a $4.00 price objective on the stock. Leerink Partners' target price suggests a potential upside of 80.18% from the company's current price.

Several other equities research analysts have also recently weighed in on IPHA. Citigroup upgraded shares of Innate Pharma from a "buy" rating to an "outperform" rating in a research report on Tuesday. HC Wainwright boosted their price target on Innate Pharma from $5.00 to $7.00 and gave the company a "buy" rating in a research note on Monday. UBS Group restated a "buy" rating on shares of Innate Pharma in a report on Tuesday. Finally, Weiss Ratings upgraded shares of Innate Pharma from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Friday, June 26th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $6.33.

Innate Pharma Stock Performance

Shares of IPHA opened at $2.22 on Tuesday. Innate Pharma has a 1 year low of $1.17 and a 1 year high of $2.62. The business has a 50-day moving average of $1.80 and a 200-day moving average of $1.67.

Hedge Funds Weigh In On Innate Pharma

Several hedge funds have recently modified their holdings of IPHA. OLD Mission Capital LLC bought a new position in shares of Innate Pharma in the fourth quarter valued at approximately $50,000. Millennium Management LLC purchased a new stake in shares of Innate Pharma during the 4th quarter valued at $36,000. Finally, Jane Street Group LLC purchased a new stake in shares of Innate Pharma during the 4th quarter valued at $162,000. Institutional investors own 0.16% of the company's stock.

About Innate Pharma

Innate Pharma SA is a clinical-stage biotechnology company specializing in the discovery and development of antibody-based therapies that harness the body's innate immune system to combat cancer. Founded in 1999 and headquartered in Marseille, France, the company pioneers novel monoclonal antibodies designed to activate natural killer cells and macrophages, offering a complementary approach to existing immuno-oncology treatments.

The company's lead program, monalizumab, targets the NKG2A immune checkpoint receptor and is being developed in collaboration with AstraZeneca.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source